Analytical tools for the analysis of clustered O-glycans in clinical samples

用于分析临床样品中聚集的 O-聚糖的分析工具

• 批准号: 9338092
• 负责人: Matthew B Renfrow
• 金额: $ 3.5万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-15 至 2020-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9338092
• 关键词: Academy; Acetylgalactosamine; Address; Amino Acid Sequence; Amino Acids; Antibodies; Antigen-Antibody Complex; Area; Autoimmune Diseases; Biological Process; Biomedical Research; Biopsy; Chronic; Chronic Kidney Failure; Clinical; Cluster Analysis; Communicable Diseases; Complex; Data; Databases; Detection; Development; Diagnostic; Disease; Disease Outcome; Disease Progression; Enzyme-Linked Immunosorbent Assay; Epitope Mapping; Epitopes; Exhibits; Fostering; Funding; Future; Galactose; Glomerulonephritis; Glycobiology; Glycopeptides; Glycoproteins; Health; Heterogeneity; Housing; IgA1; Immunoassay; Immunoglobulin A; Immunoglobulins; Individual; Inflammatory; Kidney; Kidney Diseases; Knowledge; Label; Laboratories; Lead; Lectin; Maps; Methods; Modification; Molecular; National Research Council; Outcome; Pathologic Processes; Patients; Peptides; Phenotype; Polymers; Polysaccharides; Population; Post-Translational Protein Processing; Progress Reports; Protein Analysis; Protein Glycosylation; Proteins; Publishing; Reagent; Reference Standards; Research; Role; Running; Sampling; Series; Serum; Site; Tandem Repeat Sequences; Technology; Testing; Time; Tn antigen; United States National Academy of Sciences; Viral Tumor Antigens; Work; analytical tool; base; biomarker discovery; clinical biomarkers; cohort; disorder control; glycosylated serum protein; glycosylation; insight; interest; ionization; monomer; multidisciplinary; novel; prognostic significance; public health relevance; research study; sialylation; specific biomarkers; technology development; tool

 DESCRIPTION (provided by applicant): Glycosylation is one of the most common post-translational modifications of proteins; over half of mammalian proteins are glycosylated. Patients with several autoimmune disorders, chronic inflammatory diseases, and some infectious diseases exhibit abnormal glycosylation of serum immunoglobulins and other glycoproteins. The biological functions of these modifications in health and disease continue to be a significant area of interest in biomedical research. Specifically, the task of defining site-specific glycoprotein heterogeneity is recognized as an area that still needs a considerable amount of effort to fully understand the role of glycan heterogeneity. We have developed robust workflows for the analysis of the IgA1 clustered O-glycan heterogeneity in clinical samples from patients with a chronic kidney disease, IgA nephropathy (IgAN), the most predominant form of glomerulonephritis in the world. Our outcome-based approach for profiling the entire range of IgA1 O-glycoforms from clinical samples has made significant contributions to the field of IgAN research, but also to the broader field of profiling protein glycosylation heterogeneity. Our findings have provided a means of detecting shifts in glycan heterogeneity through the application of relative quantitative, label-free analysis of the entire population of IgA1 glycofors in a single serum sample. Based on our novel workflows, we have identified subsets of IgA1 O-glycoforms in patients with IgAN that are significantly increased/decreased in their relative abundance compared to healthy controls. Going forward, absolute quantitation of individual O-glycoforms is needed. There are no established methods for the quantitative analysis of intact clustered O-glycopeptides or O-glycoproteins with Core 1 type O-glycans. Current quantitative immunoassays for detection of aberrant Core 1 glycans (Tn and sialyl-Tn antigens) are not well defined in terms of what protein, amino acid, or adjacent O-glycan context they recognize. In this proposal, we will adapt our existing methods for relative quantitative profiles into absolute quantitative strategies with O-glycopeptide reference standards. We hypothesize that this approach will provide a needed tool for heavily O-glycosylated proteins to become reliable clinical biomarkers. We have successfully synthesized in-house a series of complex clustered O-glycopeptides to serve as reference standards and novel reagents for the analysis of clustered O-glycan-specific epitopes. We will apply our quantitative strategies to the analysis of two IgAN patient cohorts to identify specific Tn antigen-presenting IgA1 O-glycoforms that lead to the formation of nephritogenic immune complexes. We will also make use of our accumulated knowledge of clustered O-glycan heterogeneity in tandem repeat amino acid sequences to characterize the accessible Tn antigen epitopes for recognition by naturally occurring and commercially available antibodies.